Q3 2015 13F Holders as of 9/30/2015
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share (the "Common Stock")
-
Shares outstanding
-
62.7M
-
Number of holders
-
125
-
Total 13F shares, excl. options
-
27.2M
-
Shares change
-
+777K
-
Total reported value, excl. options
-
$1.15B
-
Value change
-
+$22.8M
-
Put/Call ratio
-
0.45
-
Number of buys
-
81
-
Number of sells
-
-49
-
Price
-
$42.32
Significant Holders of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) as of Q3 2015
155 filings reported holding SAGE - Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") as of Q3 2015.
Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) has 125 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 27.2M shares
of 62.7M outstanding shares and own 43.38% of the company stock.
Largest 10 shareholders include Third Rock Ventures, LLC (6.44M shares), FMR LLC (4.32M shares), Redmile Group, LLC (1.14M shares), VANGUARD GROUP INC (1.13M shares), FRANKLIN RESOURCES INC (1.03M shares), ALLIANCEBERNSTEIN L.P. (914K shares), Visium Asset Management, LP (903K shares), JPMORGAN CHASE & CO (899K shares), GILDER GAGNON HOWE & CO LLC (817K shares), and EAGLE ASSET MANAGEMENT INC (752K shares).
This table shows the top 125 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.